Fezolinetant - Menopausal disorders
You are here : Home > Formulary Search > Fezolinetant - Menopausal disorders
Status 1
- Tablets
For moderate to severe vasomotor symptoms associated with menopause where hormone replacement therapy is not suitable.
For people with a history of breast cancer or other oestrogen-dependent cancers who have completed treatment, the use of fezolinetant (off-label) should be considered following an individualised risk assessment. Clinicians may seek advice from oncology and/or menopause specialists where appropriate.
Documentation
- No records returned.
PAD Profile
Committee Recommendations (1)
The Surrey and Sussex Integrated Care Board Aprea Prescribing Committee supports restricted use of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in adults, in line with NICE TA1143, where hormone replacement therapy (HRT) is not suitable
Other Indications
Below are listed other indications that Fezolinetant is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Menopausal disorders.
- Clonidine hydrochloride
- Conjugated oestrogens
- Conjugated oestrogens with medroxyprogesterone
- Drospirenone
- Duavive
- Dydrogesterone
- Estradiol
- Estradiol with drospirenone
- Estradiol with dydrogesterone
- Estradiol with levonorgestrel
- Estradiol with medroxyprogesterone
- Estradiol with norethisterone
- Estradiol with progesterone
- Ethinylestradiol
- Gabapentin
- Levonorgestrel
- Medroxyprogesterone acetate
- Non-Hormonal lubricants
- Paroxetine
- Pregabalin
- Progesterone
- St Johns Wort
- Tibolone
- Venlafaxine